38 results about "EDEMA RETINAL" patented technology

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention provides extracellular vesicle proteins sPTPRG and Vincin of a biomarker for detecting retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing, the difference of the expression quantity of the extracellular vesicle proteins in aqueous humor of a patient is analyzed, the protein with remarkable expression difference is screened out, the protein can be used as the biomarker for RVO-ME treatment, and the application of the biomarker for detecting the anti-VEGF treatment typing of the retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing of the RVO-ME anti-VEGF treatment typing is facilitated. Important guidance is provided for personalized treatment of RVO-ME, and the method has a wide clinical application prospect.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The invention is concerned with a method of predicting response to an IL-6 angatonist such as anti-IL-6 antibody by determing the concentration of IL-6 in human aqueous humor. The invention is also concerned with an IL-6 angatonist for use in treatment of uveitis or uveitic macular edema.

The present invention relates to 3, 5-diaminotriazole derivatives of formula (I) and pharmaceutical or veterinary compositions comprising such derivatives. It further relates to the use of the compounds of formula (I) for the treatment of ocular diseases, preferably diabetic retinopathy, macular degeneration, neovascular glaucoma, macular edema or Steckstroke disease.

The present invention relates to a method for the production of an ocular implant, wherein dexamethasone — commonly employed in the treatment of macular edema resulting from retinal vein occlusion (RVO) and diabetic macular edema (DME) — is encapsulated within a nanofibrous matrix fabricated via electrospinning, and said nanofibers are subsequently coated onto a contact lens surface.

The invention provides a compound medicine for treating macular edema after cataract phacoemulsification and a preparation method of the compound medicine, and relates to the field of medicines. The compound medicine is prepared from the following raw materials in parts by weight: 18 to 23 parts of herba hedyotidis diffusae, 18 to 23 parts of rhizoma alismatis, 13 to 17 parts of herba artemisiae scopariae, 13 to 17 parts of rhizoma smilacis glabrae, 13 to 17 parts of semen plantaginis, 8 to 12 parts of rhizoma atractylodis, 8 to 12 parts of fructus gardeniae, 10 to 15 parts of white hyacinth bean, 10 to 15 parts of fructus rosae laevigatae, 8 to 12 parts of semen euryales The compound medicine disclosed by the invention is used for treating the macular edema after the cataract phacoemulsification, all the medicines are coordinated and synergistic, the effects of promoting urination and attacking evil, strengthening the spleen and consolidating the foundation, eliminating evil and calming the body resistance are achieved, microcirculation is improved, expression of peripheral blood VEGF (vascular endothelial growth factor) is reduced, vascular permeability is effectively promoted, retina recovery is promoted, and the like. The traditional Chinese medicine composition has a good clinical effect on treating macular edema after cataract ultrasonic emulsification, and has no side effect.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention relates to a traditional Chinese medicine composition for treating macular edema, which is prepared from the following traditional Chinese medicines in parts by weight: 5-35 parts of astragalus mongholicus, 1-30 parts of radix rehmanniae recen, 1-30 parts of radix angelicae, 1-30 parts of rhizoma atractylodis macrocephalae and 1-30 parts of rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-30 parts of poria cocos, 1-20 parts of radix achyranthis bidentatae, 1-20 parts of moutan bark, 1-20 parts of fructus gardeniae, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of radix scrophulariae, 1-20 parts of radix ophiopogonis, 1-20 parts of radix paeoniae alba, 1-15 parts of radix curcumae, 1-10 parts of radix notoginseng and 1-10 parts of lotus leaves. The traditional Chinese medicine composition can effectively relieve macular edema after macular anterior membrane vitrectomy, has positive effects on improving the inflammatory state, microcirculation and metabolic function of a macular region of a patient, and is safe in clinical use.

An ophthalmic preparation for treating macular edema, optic neuritis and non-infectious endophthalmitis contains an active ingredient for treating eye diseases and an ophthalmic preparation carrier or auxiliary material. The active ingredient for treating eye diseases is a glucocorticoid medicine and / or a non-steroidal medicine. The ophthalmic preparation carrier or auxiliary material contains the following ingredients: a surfactant, an ionic polymer and a solvent, or the ophthalmic preparation carrier or auxiliary material contains the following ingredients: povidone with low polymerization degree, povidone with moderate polymerization degree and a solvent. The ophthalmic preparation can carry (wrap) the glucocorticoid and / or the non-steroidal medicines to penetrate through the anterior segment of eyes and be conveyed to the posterior segment of eyes to treat the macular edema, the optic neuritis and the non-infectious endophthalmitis in an eye drop administration mode, and the ophthalmic preparation has extremely excellent clinical use value and positive social significance.

To provide treatment of AMD using an AAV2 variant with aflibercept.SOLUTION: The present disclosure provides pharmaceutical compositions and methods thereof for treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept. The present disclosure relates to pharmaceutical compositions and methods for prevention or treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME, retinal vein occlusion, and related eye diseases or conditions, in a primate or human subject by administering intravitreally or subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector or viral particles (e.g., rAAV) comprising a nucleic acid encoding aflibercept or a functional fragment or variant thereof.SELECTED DRAWING: None

The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

The invention provides a traditional Chinese medicine composition used in the perioperative period of fundus surgery and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition for the perioperative period of the fundus surgery is prepared from the following components in parts by weight: 9 to 15 parts of radix astragali seu hedysari, 6 to 12 parts of radix angelicae sinensis, 6 to 12 parts of radix rehmanniae, 6 to 12 parts of herba ecliptae, 3 to 9 parts of radix paeoniae rubra, 3 to 9 parts of rhizoma atractylodis macrocephalae, 6 to 12 parts of semen plantaginis, 1 to 6 parts of radix saposhnikoviae and 1 to 6 parts of ramulus cinnamomi. By adopting the traditional Chinese medicine composition, the postoperative vision of a patient subjected to fundus surgery can be effectively improved, the retina sensitivity is improved, and the visual function of a macular region is improved; absorption of fundus hemorrhage is effectively promoted, the central fovea thickness of a macular region is reduced, and absorption of postoperative macular edema is promoted; the traditional Chinese medicine composition can improve eye local and whole body traditional Chinese medicine syndromes, and is safe in clinical medication.

The present invention relates to a method for predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The present invention also relates to an IL-6 antagonist for use in treating uveitis or uveitic macular edema.

The present invention relates to novel methods, uses and compositions of annexin A5 protein as combination therapy with one or more anti-VEGF agents, the present invention relates to compounds, for example, for the prevention or treatment of macular edema, retinal vein occlusion and / or one or more diseases, conditions or conditions associated with and / or caused by macular edema or retinal vein occlusion, and / or other conditions suitable for treatment with anti-VEGF agents. In a preferred embodiment, the annexin A5 is administered systemically, such as intravenously.

Provided herein are methods of treating an eye disorder, including, for example, diabetic macular edema (DME) or macular edema secondary to inflammation (MESI) or wet age-related macular degeneration (wAMD), by administering a fusion protein and / or a conjugate thereof to a subject in need thereof.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The application discloses a kind of based on MEA-Net network's modeling method of multi-expert system, the application includes data pre-processing, cutting and proportionally distributing production image data and label data set;In order to improve fundus retinal lesion classification accuracy, the application designs Multi-Expert attention Net network model.Input module is preliminary extracted to data, replaceable expert network module is responsible for the depth analysis of feature, and voting module is strengthened by separating channel adjacent module on channel space to feature, and output weight realizes expert voting, finally, classification result is obtained by output module.The application can use the picture information of optical coherence tomography, can analyze and extract the characteristics of the four types of macular edema degeneration performances of OCT image PED, SRF, IRF, HRF, and lay the foundation for subsequent retinal disease classification and analysis to improve efficiency.

The invention relates to the technical field of image data processing, in particular to a macular oedema dynamic change monitoring method based on an OCT (optical coherence tomography) tomographic image, which comprises the following steps: acquiring a reference OCT image, a micro-angle change OCT image and an OCTA blood flow image of an eye macular area of a patient; determining the change intensity of pixel points by using a gray value change sequence in the OCTA blood flow image sequence, and determining a macular oedema existing area in the reference OCT image based on the change intensity; performing peak detection on the gray histogram of the macular oedema existing area based on the gray features of the cyst area to obtain a cyst candidate area; and determining a cyst candidate area, and obtaining a cyst area in the reference OCT image by using a gray value sequence of pixel points in the aligned cyst candidate area. According to the method, the influence of the vessel shadow is eliminated, the segmented cyst part is more accurate and complete, and the dynamic change monitoring effect is remarkably improved.

The invention provides a construction method of a retinal vein occlusion animal model, and belongs to the technical field of medicines. The method comprises the following steps of: performing eyeball surface anesthesia on an anesthetized non-human primate animal, puncturing an eyeball after disinfection to establish two sclera tunnels, respectively inserting an illumination optical fiber and an intraocular laser optical fiber into the two sclera tunnels, then injecting a photosensitizer through limb vein, immediately performing laser photocoagulation on the retinal vein under illumination of the illumination optical fiber after injection, and performing laser photocoagulation on the retinal vein under the illumination of the illumination optical fiber. And obtaining the retinal vein occlusion animal model. According to the method, the retinal vein occlusion model can be successfully constructed, secondary macular edema and vascular recanalization are carried out for a long time and can be maintained for 4-5 weeks, the manifestation sign of retinal hemorrhage after retinal vein occlusion is close to that of human beings, and the method has clinical drug responsiveness, shows the clinical research value and has good application prospects. And a good research model is provided for research in the aspects of etiology, pathology and therapeutics.

The present disclosure relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound for the treatment of ocular diseases. The ocular diseases include, but are not limited to, proliferative vitreoretinopathy, cystoid macular edema, central serous retinopathy, diabetic retinopathy, endophthalmitis, epiretinal membrane, and toxoplasmosis. The present disclosure also relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound to inhibit glial scar formation or reduce glial scar length.

The invention discloses a macular oedema lesion screening method and system based on prototype dynamic pseudo tags, belongs to the technical field of macular oedema lesion screening, and aims to solve the technical problem of low macular oedema lesion screening accuracy in the prior art. The method comprises the following steps: acquiring OCT image sample data, macular oedema negative and positive labels, full labeling labels and point labeling labels; a macular oedema lesion segmentation model is constructed and trained, the macular oedema lesion segmentation model comprises a UNet encoder, a strong branch UNet decoder, a weak branch UNet decoder and an attention mechanism module, feature vectors output by the UNet encoder serve as input of the strong branch UNet decoder and the weak branch UNet decoder, and feature vectors output by the strong branch UNet decoder and the weak branch UNet decoder serve as input of the attention mechanism module. The outputs of the UNet encoder and the weak branch UNet decoder are used as the input of the attention mechanism module; and obtaining an OCT image to be detected, inputting the OCT image to the model, and obtaining a macular edema lesion screening result after a feature map E output by the UNet encoder and a segmentation prediction map S output by the weak branch UNet decoder pass through an attention mechanism module.

The invention provides a fundus macular oedema image processing method based on improved YOLOv11 and DeepSeek, and relates to the technical field of ophthalmic disease screening, and the method specifically comprises the steps: employing an improved YOLOv11 network structure, adding a lightweight dynamic convolution module LDConv module and a convolution block attention module CBAM, dynamically adjusting the shape and size of a convolution kernel, and carrying out the detection of the fundus macular oedema image. Multi-scale lesion characteristics such as macular edema and exudates are accurately captured; an attention map is generated through a channel and a space attention mechanism, key lesion areas of macular edema are preferentially concerned, interference of background noise is inhibited, and therefore accuracy and robustness of lesion recognition are further improved; a DeepSeek large language model is introduced, and on the basis of a detection result, personalized diagnosis and treatment suggestions conforming to clinical guidelines are generated in combination with clinical information (such as age, pathogenesis and treatment history) of patients; the system provides a structured treatment scheme and a follow-up visit plan and assists doctors in making more scientific and personalized decisions.

This invention relates to the application of an AAV carrying anti-VEGF recombinant protein in the prevention or treatment of proliferative diabetic retinopathy. After loading Fc-engineered VEGF antibody into an AAV vector, it can be used in drugs for the treatment of proliferative diabetic retinopathy. After injection, it can significantly improve the visual function of patients and reduce macular edema after a single dose. The anti-VEGF recombinant protein can be expressed for a long time, and can maintain the drug effect over a long period of time.

The present disclosure relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound for the treatment of ocular diseases. The ocular diseases include, but are not limited to, proliferative vitreoretinopathy, cystoid macular edema, central serous retinopathy, diabetic retinopathy, endophthalmitis, epiretinal membrane, and toxoplasmosis. The present disclosure also relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound to inhibit glial scar formation or reduce glial scar length.